Android app Apple app link

Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder

By Yahoo! Finance   |   1 month ago
Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder

Rhythm Pharmaceuticals reported positive results from the Phase 3 TRANSCEND trial of setmelanotide for acquired hypothalamic obesity, showing significant reduction in BMI with no new safety concerns.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.